Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Eagle Pharmaceuticals excels in 2022 with strong earnings growth

Eagle Pharmaceuticals' 2022 performance reflects strong earnings growth and operational efficiency, supported by key product sales and financial stability.
While facing challenges in managing expenses amidst investments, the company's strategic strengths lie in its product portfolio and financial resilience.
Opportunities for revenue growth and market expansion present avenues for Eagle Pharmaceuticals to further enhance its competitive position and drive future success.

Eagle Pharmaceuticals posts robust Q1 results, eyes strategic growth opportunities

Eagle Pharmaceuticals delivered a strong financial performance in Q1 2023, driven by key product sales and market share retention.
While facing challenges in expenses management, the company's solid cash position and growth strategies position it well for future opportunities.
Strategic initiatives like potential acquisitions and market expansion underscore Eagle Pharmaceuticals' commitment to sustained growth and innovation.

Eagle Pharmaceuticals beats Q2 estimates, eyes growth through strategic investments

Eagle Pharmaceuticals delivered a robust Q2 performance, exceeding expectations and demonstrating strong financial health. The company's strategic investments in R&D and commercial infrastructure position it well for future growth. Despite challenges and uncertainties, Eagle Pharmaceuticals remains optimistic about its continued growth trajectory and market prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.68% and 1.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Surpass Estimates

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 63.16% year over year to $0.93, which beat the estimate of $0.80.

Recap: Eagle Pharmaceuticals Q2 Earnings

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and six months ended June 30, 2021. Business and Recent Highlights: Entered into a licensing agreement for the U.S. commercial rights to Landiolol, a leading hospital emergency use product in Europe and Japan. Landiolol is currently approved in Europe for the treatment of non-compensatory sinus tachycardia and tachycardic supraventricular a

Eagle Pharmaceuticals Reports Second Quarter 2021 Results

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (“AOP Orphan”), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non-

Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 second quarter financial results on Monday, August 9, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date     Monday, August 9, 2021 Time     8:30 a.m. ET Toll free (U.S.)     877-876-9173 International

Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug and Administration (“FDA”) has maintained Priority Review for the Company's Abbreviated New Drug Application (“ANDA”) for vasopressin. The Company's response to the CRL was submitted on June 15, 2021. The FDA has assigned a GDUFA date of December 15, 2021, and the Company expects a commercial launch prior to year-end. “Vasopressin is an importa

Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has responded to the Complete Response Letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin received from the U.S. Food and Drug Administration (“FDA”) in February 2021. “We appreciate FDA's insights and based on our post-CRL meeting, believe that we have now responded fully and completely to the CRL. Our ANDA is currently prioritized b

Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin

Eagle Pharmaceuticals has felt the impact of COVID-19, and the earnings reports have reflected that. As a result, the share price has taken a beating over the past year.

Eagle Pharmaceuticals: A Potential Reopening Play

New York, New York--(Newsfile Corp. - June 11, 2021) - Levi & Korsinsky announces it has commenced an investigation of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/eagle-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Eagle Pharmaceuticals, Inc.- EGRX

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows: Date:   Wednesday, June 2, 2021 Time:   1:30 p.m. Eastern Time Webcast:   https://wsw.com/webcast/jeff174/egrx/1863162 The presentations will be webcast live at the aforementioned times, and archived for 30 da

Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

New York, New York--(Newsfile Corp. - May 14, 2021) - Levi & Korsinsky announces it has commenced an investigation of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/eagle-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Eagle Pharmaceuticals, Inc.- EGRX

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference as follows: Date: Tuesday, May 18, 2021 Time: 1:20 p.m. Eastern Time Webcast: https://event.on24.com/wcc/r/3173733/CEA9B803E5C77274A4417D4FE2A0EAB0 The presentation will be webcast live at the aforementioned time

Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc.'s (EGRX) CEO Scott Tarriff on Q1 2021 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -66.67% and -9.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Miss Estimates

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share decreased 71.43% year over year to $0.24, which missed the estimate of $0.65.

Recap: Eagle Pharmaceuticals Q1 Earnings

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three months ended March 31, 2021. Business and Recent Highlights: Completed the last study required by FDA for the Company's vasopressin product and expect to have the results shortly. Eagle plans to respond to the CRL issued for its first-to-file Abbreviated New Drug Applicable (“ANDA”) for vasopressin in full by mid-year. The Company's patent

Eagle Pharmaceuticals Reports First Quarter 2021 Results

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that TREAKISYM RI (50ml) liquid formulation has been filed with the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan. The application is based on the results of clinical studies investigating the safety and pharmacokinetics of TREAKISYM RTD administered by 10-minute intravenous infusion. “We are pleased that the RI application has been submitted ahead of sched

Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Luciana (“Lu”) Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regulatory and policy initiatives on behalf of the U.S. government, notably in her roles at the U.S. Food and Drug Administration (“FDA” or “Agency”). “We are delighted to welcome Lu to the Eagle Board of Directors. Lu i

Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that TREAKISYM ready-to-dilute (“RTD”) (bendamustine hydrochloride 120 mg/m2) liquid formulation has been approved for a new indication in combination with rituximab (“BR therapy”) as treatment for relapsed or refractory diffuse large B-cell lymphoma (“r/r DLBCL”) by the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan. “This latest approval is another meaning

Eagle Pharmaceuticals Announces TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) Formulation, in Combination with Rituximab for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Receives PMDA Approval in Japan

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 first quarter financial results on Monday, May 10, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Monday, May 10, 2021 Time 8:30 a.m. ET Toll free (U.S.) 877-876-9173 International 785-424-1667 Webcast (l

Eagle Pharmaceuticals to Host First Quarter 2021 Financial Results on May 10, 2021

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2020 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 323.26% and -0.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings Estimates

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 100.00% year over year to $0.96, which may not compare to the estimate of ($0.17).

Eagle Pharmaceuticals: Q4 Earnings Insights

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2020, and reviewed key pipeline programs. Business and Recent Highlights: Posted strong year-over-year adjusted non-GAAP earnings growth of 36%; Received a complete response letter (“CRL”) from U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Ea

News for Eagle Pharmaceuticals Stock (EGRX)